-

Bone Solutions Launches Mg OSTEOINJECT Injectable Magnesium-Based Bone Void Filler

COLLEYVILLE, Texas--(BUSINESS WIRE)--Bone Solutions Inc. (BSI), an orthobiologics technology company located in Colleyville, Texas, announced today the immediate commercial launch of Mg OSTEOINJECT, the first injectable bone void filler in the U.S. to incorporate magnesium - a critical component for bone health and development. This flowable product is designed to promote bone repair and regeneration within insufficiency and micro fractures.

“We are excited to bring our latest innovative orthopedic technological advancement to surgeons and their patients,” stated BSI president and CEO, Drew Diaz. “As the only magnesium-based bone repair product for insufficiency fractures, Mg OSTEOINJECT provides a surgical solution that is unlike anything currently available on the market.”

The efficacy of magnesium was a key component of BSI’s approach to developing the Mg OSTEOINJECT technology. Magnesium contains high specific strength and a modulus of elasticity that closely resembles human bone. Approximately 60% of magnesium in the body resides in the bones, contributing to the structural development of bone and playing a key role in the absorption and regulation of calcium. Because of these characteristics, Mg OSTEOINJECT is resorbable and is designed to safely assimilate back into the body during the healing process as it is replaced with bone.

Mg OSTEOINJECT is currently being distributed to facilities and surgical centers nationwide for immediate clinical use.

About Bone Solutions Inc.

Bone Solutions Inc. (‘BSI’) is a specialized medical device company dedicated to improving clinical outcomes through biologically safe, fully resorbable magnesium-based orthopedic implant solutions, with a focus on addressing complex procedures and cost reduction. The company is developing various new orthopedic technologies within its FDA-cleared magnesium-based platform.

“Mg OSTEOINJECT” is a registered trademark of Bone Solutions, Inc.

Contacts

Media Contact:
Paul Williams, MediaLine Communications, 310-569-0023
paul@medialinecommunications.com

Company Contact:
Drew Diaz, Bone Solutions Inc., 817-809-8850
diaz@bonesolutions.net

Bone Solutions Inc.


Release Summary
Bone Solutions has launched Mg OSTEOINJECT, the first injectable bone void filler in the US to incorporate magnesium.
Release Versions

Contacts

Media Contact:
Paul Williams, MediaLine Communications, 310-569-0023
paul@medialinecommunications.com

Company Contact:
Drew Diaz, Bone Solutions Inc., 817-809-8850
diaz@bonesolutions.net

Social Media Profiles
More News From Bone Solutions Inc.

Bone Solutions’ Mg OSTEOCRETE and Mg OSTEOINJECT Receive FDA Clearance for Pediatric Use in Patients Aged Six and Older

COLLEYVILLE, Texas--(BUSINESS WIRE)--Bone Solutions Inc., a Colleyville-based orthobiologics company specializing in magnesium-based technologies, announced that the U.S. Food and Drug Administration (FDA) has granted pediatric clearance for its Mg OSTEOCRETE and Mg OSTEOINJECT products. The clearance allows use of the technologies in pediatric patients aged six years and older. This expanded indication highlights the adaptability of Bone Solutions’ proprietary magnesium-based platform, particu...

Bone Solutions Announces Five New Patents Awarded in FY25, Further Enhancing Its Core Mg OSTEOCRETE Technology

COLLEYVILLE, Texas--(BUSINESS WIRE)--Bone Solutions Inc., an orthobiologics technology company located in Colleyville, Texas, announced today its fifth patent awarded this year from the U.S. Patent and Trademark Office (USPTO) related to Mg OSTEOCRETE, a portfolio of patents that includes current and future configurations, as well as novel delivery systems. These five patents further expand Bone Solutions’ industry footprint and allow surgeons and patients to further benefit from the advantages...

Bone Solutions Receives 510(k) Clearance for Expanded Indications of Use for Mg OSTEOCRETE in Intervertebral Body Fusion Procedures

COLLEYVILLE, Texas--(BUSINESS WIRE)--Bone Solutions Inc., an orthobiologics technology company located in Colleyville, Texas, announced today 510(k) clearance of Mg OSTEOCRETE from the U.S. Food and Drug Administration (FDA) for use in the intervertebral body disc space, including cervical, thoracic, and lumbar fusion procedures. This marks the first and only magnesium-based bone substitute to be cleared by the FDA for this application. This expanded indication allows surgeons and patients to f...
Back to Newsroom